Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ studyCharles V. Pollack, Jeffrey I. Weitz, Fredrik Gruenenfelder et al.|Journal of Medical Economics|2016Cited by 11
IDARUCIZUMAB FOR REVERSAL OF THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONSCharles V. Pollack, Jeffrey I. Weitz, Paul Reilly et al.|Journal of the American College of Cardiology|2016Cited by 2